Important COVID-19 information: All event teams are taken action to ensure health and safety of all delegates. This will result in postponement, change to e-seminar or other changes. Please visit the event pages to get the latest information. If you follow the event you will be updated on the latest changes. Please stay safe in these difficult times.

Past event: Drug Development Forum

The Intersection of Drug Development, Deal-Making, and Business Strategy

As many blockbuster products face the loss of exclusivity, life science organizations face staunch competition from generic and biosimilar products to maintain their stronghold in certain markets. There is a lot riding on the success of new drug development, and companies are increasingly turning to external sources of innovation to supplement organic pipeline growth and replace key products within their portfolios.

Biotechs continue to push the boundaries of R&D innovation, exploring specialized areas of research, often entering undefined, first-in-class territory. However, changing regulatory requirements, payer expectations, and investor demands make drug development and commercialization an increasingly risky endeavor, leaving little to no margin for error. It takes strong leadership, a well-articulated and communicated shared vision, and innovative partnerships to navigate the competitive landscape and ensure the successful development of a commercially viable product in today's healthcare environment.

The 4th Drug Development Forum features executive leadership perspectives from biotech and big pharma companies on emerging trends and market dynamics that will help effectively prioritize R&D spend and unlock the potential of a licensing, joint venture or M&A deal.

Attendees can look forward to the following benefits

  • Interact with biotech, mid-sized and large pharma company leaders and trade ideas for tackling the biggest industry challenges, from preclinical research through pivotal trials and beyond
  • Optimize early phase clinical activity to ensure successful trial execution and regulatory approval
  • Discuss innovative deal structures and investment models that can de-risk collaborations and partnerships and help assist the development of drugs
  • Hear how companies build business cases to support new product development and prioritize capital allocation for the R&D budget
  • Consider the pros and cons associated with different sources of financing and determine how that can impact a company's long-term goals
  • Understand the risks and rewards of commercializing a product on your own vs. finding a strategic partner
  • Discuss critical questions small companies should ask when evaluating potential partners
  • Develop a go-to-market/launch strategy that successfully differentiates your product and provides the best possible outcomes for patients

Who Attends?

This event is aimed at professionals in the pharmaceutical, biotech, medical device and venture capitalist fields responsible for:
  • Business Development
  • Corporate Development
  • Mergers and Acquisitions
  • Alliance Management
  • Partnering
  • Portfolio Management
  • Vendor Management
  • Licensing
  • Clinical Operations
  • Clinical Research/Clinical Development
  •  Strategy/Product Strategy/Strategic Development
  • Clinical Trial Management
  • Data Management
  • Innovation
  • Investments
  • R&D
  • Regulatory Affairs
This event is also of interest to:
  • CROs
  • Supply Chain Professionals
  • Law Firms
  • Clinical Data Management Specialists
  • Business Development Specialists

Featured Speakers

  • Pearl S. Huang, Ph.D., President and CEO, CYGNAL THERAPEUTICS
  • Lizabeth Leveille, Associate Vice President and Head, Boston Innovation Hub, BD&L, MERCK
  • James Robinson, President and Chief Operating Officer, PARAGON BIOSCIENCES
  • Emily Minkow, Chief Business Officer, PREVAIL THERAPEUTICS
  • Elliott M. Levy, M.D., Senior Vice President, Global Development, AMGEN
  • David Weinreich, M.D., MBA, Senior Vice President, Global Clinical Development, REGENERON
  • Molly Harper, Senior Vice President and Global Franchise General Manager, AKCEA THERAPEUTICS
  • Lotus Mallbris, M.D., Ph.D., Vice President, Immunology Development, ELI LILLY AND COMPANY
  • Robert Bagdorf, M.D., M.B.A., Group Lead, Search and Evaluation, Worldwide Business Development, PFIZER
  • Kleem Chaudhary, Ph.D., Head BD&L, BIOGEN
  • Rich Daly, Chief Operating Officer, BEYONDSPRING PHARMACEUTICALS

Please fill in your name and email to receive the Conference Agenda of this event.


The Colonnade Hotel
120 Huntington Ave., 02116
Boston, MA, USA

To make reservations guests can call 617-424-7000 or 800-962-3030 and request the group rate for 'DDF2019'. To make reservations online click here.  

The group rate is available until October 7, 2019. Please book your room early as rooms available at this rate are limited.
Event details
Organizer : ExL
Event type : Training Course
Reference : ASDE-21524